Gender differences in association of plasma adiponectin with obesity reflect resultant insulin resistance in non-diabetic Japanese patients with schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 59, Issue 3, 2005, Pages 266-273

  Matsuda, Yukihiko ^a   Tanioka, Tetsuya ^b   Yoshioka, Takaoki ^a   Nagano, Takamasa ^a   Hiroi, Tadashi ^a   Yoshikawa, Kenichi ^a   Okabe, Ken Ichiro ^a   Nagamine, Isao ^b   Takasaka, Yoichiro ^a  

^a Hosogi Unity Hospital   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Adiponectin; Insulin resistance; Leptin; Obesity; Schizophrenia

Indexed keywords

ADIPONECTIN; ATYPICAL ANTIPSYCHOTIC AGENT; BENZAMIDE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CHLORPROMAZINE; CYTOKINE; INSULIN; LEPTIN; OLANZAPINE; PEROSPIRONE; PHENOTHIAZINE DERIVATIVE; QUETIAPINE; RISPERIDONE; THIEPIN DERIVATIVE;

ADIPOSE TISSUE; ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY FAT; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; JAPAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; SCHIZOPHRENIA; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADIPONECTIN; ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CROSS-SECTIONAL STUDIES; FEMALE; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; JAPAN; LEPTIN; MALE; MIDDLE AGED; OBESITY; SCHIZOPHRENIA; SEX CHARACTERISTICS;

EID: 21244504569     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2005.01370.x     Document Type: Article

References (46)

1. Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 1999; 156: 1686-1696.
2. Taylor DM, McAskill R. Atypical antipsychotics and weight gain - a systemic review. Acta Psychiatr. Scand. 2000; 101: 416-432.
3. Wirshing DA, Wirshing WC, Kysar L et al. Novel antipsychotics: comparison of weight gain liability. J. Clin. Psychiatry 1999; 60: 358-363.
4. Dwyer DS, Bradley RJ, Kablinger AS, Freeman AM III. Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Ann. Clin. Psychiatry 2001; 13: 103-113.
5. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry 2002; 159: 561-566.
6. Buse JB. Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J. Clin. Epidemiol. 2003; 56: 164-170.
7. Muench J, Carey M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J. Am. Board Fam. Pract. 2001; 14: 278-282.
8. Ananth J, Venkatesh R, Burgoyne K, Gunatilake S. Atypical antipsychotic drug use and diabetes. Psychother. Psychosom. 2002; 71: 244-254.
9. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002; 6: 77-89.
10. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J. Clin. Psychiatry 2001; 62 (Suppl. 23): 30-38.
11. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J. Clin. Psychiatry 2001; 62 (Suppl. 27): 15-26.
12. Fontaine KR, Heo M, Harrigan EP et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychol. Res. 2001; 101: 277-288.
13. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretary organ. Proc. Nutr. Soc. 2001; 60: 329-339.
14. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr. Opin. Lipidol. 2002; 13: 51-59.
15. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 1996; 334: 292-295.
16. Hotta K, Funahashi T, Bodkin NL et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50: 1126-1133.
17. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 2001; 86: 1930-3515.
18. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999; 257: 79-83.
19. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1595-1599.
20. Lindsay RS, Funahashi T, Hanson RL et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 57-58.
21. Spranger J, Kroke A, Mohlig M et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226-228.
22. Kraus T, Haack M, Schuld A et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am. J. Psychiatry 1999; 156: 312-314.
23. Melkerson KI, Hulling AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J. Clin. Psychiatry 2000; 61: 724-749.
24. Hagg S, Soderberg S, Ahren B, Olsson T, Mjorndal T. Leptin concentrations are increased in subjects with clozapine or conventional antipsychotics. J. Clin. Psychiatry 2001; 62: 843-848.
25. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J. Clin. Psychiatry 2003; 64: 598-604.
26. Togo T, Kojima K, Shoji M et al. Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study. Int. Clin. Psychopharmacol. 2004; 19: 37-40.
27. The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes mellitus. Report of the committee on the classification and diagnosis criteria of diabetes mellitus. Diabetes Res. Clin. Pract. 2002; 55: 65-85.
28. The Examination Committee of Criteria for Obesity Disease' in Japan Japan Society for the Study of Obesity. New criteria for Obesity' in Japan. Circ. J. 2002; 66: 987-992.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
30. Matsumoto K, Miyake S, Yano M et al. Glucose tolerance, insulin secretion, and insulin sensitivity in non-obese and obese Japanese subjects. Diabetes Care 1997; 20: 1562-1568.
31. Nishizawa H, Shimomura I, Kishida K et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002; 51: 2734-2741.
32. Baptista T, Reyes D, Hernandez L. Antipsychotic drugs and reproductive hormones: relationship to body weight regulation. Pharmacol. Biochem. Behav. 1999; 62: 409-417.
33. Maeda N, Takahashi M, Funahashi T et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099.
34. Yu JG, Javorschi S, Hevener AL et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51: 2968-2974.
35. Ohsumi J, Sakakibara S, Yamaguchi J et al. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology 1994; 135: 2279-2282.
36. Fasshauer M, Klein J, Newmann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2002; 290: 1084-1089.
37. Maeda N, Shimomura I, Kishida K et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nature Med. 2002; 8: 731-737.
38. Newcomer JW, Haupt DW, Fucetola R et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry 2002; 59: 337-345.
39. Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur. J. Endocrinol. 2002; 147: 173-180.
40. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001; 7: 941-946.
41. Berg AH, Du Combs TPX, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 2001; 7: 947-953.
42. Takahashi M, Arita Y, Yamagata K et al. Genomic structure and mutations in adipose-specific gene, adiponectin. Int. J. Obes. 2000; 24: 861-868.
43. Kondo H, Shimomura I, Matsukawa Y et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002; 51: 2325-2328.
44. Yamamoto Y, Hirose H, Saito I, Nishikai K, Saruta T. Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J. Clin. Endocrinol. Metab. 2004; 89: 87-90.
45. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am. J. Psychiatry 2003; 160: 284-289.
46. Tanaka Y, Matsuoka K, Atsumi Y et al. Usefulness of revised fasting plasma glucose criterion and characteristics of the insulin response to an oral glucose load in newly diagnosed Japanese diabetic subjects. Diabetes Care 1998; 21: 1133-1137.